Blueprint Medicines Reports Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Blueprint Medicines (BPMC) Misses Q3 EPS by 15c
October 30, 2018 7:11 AM EDTBlueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($1.66), $0.15 worse than the analyst estimate of ($1.51). Revenue for the quarter came in at $1.1 million versus the consensus estimate of $6.86 million.
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.
... More